Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Enovix (NASDAQ:ENVX) Shares Down 4.2% - Here's Why

Enovix logo with Industrials background
Image from MarketBeat Media, LLC.

Key Points

Shares of Enovix Corporation (NASDAQ:ENVX - Get Free Report) fell 4.2% during trading on Monday. The company traded as low as $2.41 and last traded at $2.3850. 1,169,735 shares were traded during mid-day trading, a decline of 83% from the average session volume of 6,804,836 shares. The stock had previously closed at $2.49.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of Enovix in a research note on Thursday, August 13th. Northland Securities set a $5.00 target price on Enovix in a research report on Tuesday, October 13th. TD Cowen raised Enovix to a "hold" rating in a research note on Monday, October 5th. Craig Hallum set a $7.00 price target on shares of Enovix in a research report on Thursday, August 13th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Enovix in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Enovix currently has an average rating of "Moderate Buy" and an average price target of $10.77.

Check Out Our Latest Report on ENVX

Enovix Stock Down 2.2%

The stock's 50 day simple moving average is $3.18 and its two-hundred day simple moving average is $5.01. The firm has a market cap of $534.36 million, a P/E ratio of -2.99 and a beta of 2.49. The company has a debt-to-equity ratio of 2.46, a current ratio of 9.71 and a quick ratio of 9.37.

Enovix (NASDAQ:ENVX - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. Enovix had a negative return on equity of 64.50% and a negative net margin of 473.89%. The business had revenue of $9.02 million for the quarter, compared to analysts' expectations of $8.43 million. During the same period in the prior year, the firm posted ($0.13) EPS. The firm's quarterly revenue was up 20.8% on a year-over-year basis. Enovix has set its Q3 2026 guidance at -0.170--0.130 EPS. As a group, research analysts forecast that Enovix Corporation will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Enovix

A number of institutional investors have recently bought and sold shares of ENVX. BlackRock Inc. bought a new stake in Enovix during the second quarter valued at about $100,054,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enovix in the second quarter worth about $8,689,000. Bank of America Corp DE bought a new position in shares of Enovix in the second quarter worth about $8,356,000. Refined Wealth Management boosted its stake in shares of Enovix by 0.7% in the third quarter. Refined Wealth Management now owns 850,768 shares of the company's stock worth $2,467,000 after acquiring an additional 5,918 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Enovix during the second quarter worth about $3,551,000. 50.92% of the stock is owned by institutional investors.

Enovix Company Profile

(Get Free Report)

Enovix Corporation is a battery technology company developing lithium-ion batteries that use a silicon-based anode and a three-dimensional cell architecture. The company's design is intended to increase energy density while incorporating structural features designed to improve safety and cycle life compared with conventional lithium-ion batteries.

Enovix is focused initially on batteries for consumer electronics, including smartphones, wearable devices and other mobile products. It has also identified applications in industrial, medical, aerospace, defense and electric vehicle markets.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enovix Right Now?

Before you consider Enovix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.

While Enovix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines